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Introduction
The major problem in xenotransplantation between discordant species, such as pig to human, is a process called hyperacute rejection. Hyperacute rejection is a severe immunological reaction of the recipient against the vascularised graft, leading to rapid destruction after transplantation. Natural xenoreactive antibodies present in human serum react with donor graft cells and the resultant immune complexes activate complement via the classical pathway which causes the endothelial cell damage preceding graft rejection. 1, 2 We are seeking to exploit the fundamental mechanism of hyperacute rejection as a means to treat cancer.
In the classical (antibody-dependent) pathway of complement activation the F c domain of surface-bound antibody binds to subunit C1q of complement component C1. This initiates a series of proteolytic events. Activation of C3 is a key step, with later components (C5-C9) associating to generate a 'membrane attack complex', leading to cell lysis. Because of the potency of the complement system there are many measures to prevent unwanted host cell lysis. Chief among these are the species-specific cell surface complement regulatory proteins CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF) and CD59 (protectin). CD46 and CD55 (␣1,3)galactosyl transferase (␣1,3GT) being responsible for transfer of the terminal galactose residue in ␣1,3 linkage to the substrate Gal(␤1,4)GlcNAc-R. This enzyme has been found active in non-primate mammals and New World monkeys but not in Old World primates, including humans. Old World primates do not have a functional gene for this enzyme and therefore lack the Gal(␣1,3)Gal epitope. Instead, they produce antibodies reactive with this structure (anti-Gal antibodies) 7 in response to continual exposure and antigenic stimulation by gastrointestinal bacteria. 8 It is this anti-Gal antibody that mediates hyperacute rejection. 9 Approximately 1% of human circulating B cells produce anti-Gal antibody, 10 while estimates of antibody abundance with this specificity are 1-2.4% of circulating IgG 11, 12 and 3.9-8% of IgM. 12 While there is much effort in the field of xenotransplantation directed towards limiting hyperacute destruction of the non-self cells of potential donor organs, efforts in the field of gene therapy for cancer are directed towards destruction of self-derived cells. Conventional approaches to this end are expression of genes for prodrug activation or enhanced immunogenicity, with efficacy limited by the therapeutic index of the prodrug or expression of tumour-specific antigens, respectively. We reasoned that Gal(␣1,3)Gal expression by human target cells should lead to complement activation and lysis simply by exposure to serum and that this could form the basis of a novel approach for cancer gene therapy, requiring neither drugs nor the induction of specific immunity. Preliminary evidence that human cells could be sensitised in this way was provided during studies on sensitisation of enveloped viruses to human serum by Gal(␣1,3)Gal. 13, 14 However, these studies did not determine the mechanism of cell lysis nor the generality of this phenomenon. In this study, we sought to answer these questions, establish the limitations to cell lysis by mimicry of the molecular mechanisms of hyperacute rejection in vitro, and thus evaluate the feasibility of this approach. Our target cells included those of both tumour and vascular endothelial origin, both of which are appropriate targets for cancer therapy. We conclude that mimicry of hyperacute rejection following gene transfer of ␣1,3GT is a promising new strategy for cancer gene therapy.
Results
Retroviral gene transfer of (␣1,3)galactosyl transferase to human cells results in surface expression of Gal(␣1,3)Gal Four human cell lines and a primary melanoma cell culture were infected with an amphotropic retroviral vector encoding porcine ␣1,3GT. Surface expression of the Gal(␣1,3)Gal epitope was analysed by flow cytometry using FITC-conjugated BS-IB 4 , a lectin specific for this carbohydrate structure. Bulk populations containing low and high expressing cells were obtained. Gal(␣1,3)Galhigh expressing cell populations of transduced melanoma and EAhy926 were flow sorted, and high expressing clones of transduced HT1080 and TE671 were identified following subcloning. The selected cell populations/clones are referred to below as Mel␣, EAhy926␣, HT1080␣ and TE671␣. The level of Gal(␣1,3)Gal expression for all ␣1,3GT-transduced cells was comparable with that of murine 3T3 cells, which have endogenous ␣1,3GT activity ( Figure 1a) . Expression of this epitope was similarly detected by incubation of the cells in human serum followed by detection of bound natural antibodies with anti-human Ig (data not shown). Additionally, ␣1,3GT-transduced cells and nontransduced controls were negative for expression of blood group B antigen when stained using a specific monoclonal antibody (data not shown).
Our choice of target cells included two of endothelial cell origin: ECV304 and EAhy926. The enzyme (␣1,2)fucosyl transferase (␣1,2FT or H-transferase) is known to be functional in endothelial cells and recent reports have suggested that synthesis of Gal(␣1,3)Gal epitopes is incompatible with expression of ␣1,2FT. 15 This was proposed to be because the Gal(␤1,4)GlcNAc-R substrate is common to ␣1,2FT and ␣1,3GT and due to the earlier location of ␣1,2FT within the glycosylation modification pathway in the Golgi. 16 We therefore examined endogenous ␣1,2FT expression by flow cytometry using FITC-conjugated UEA-I lectin to detect Fuc(␣1,2)Gal. Both ECV304 and EAhy926 were positive, while melanoma, TE671 and HT1080 cells were negative (data not shown). In contrast to previous reports, endogenous ␣1,2FT activity in endothelial cells was not prohibitive for expression of cell surface Gal(␣1,3)Gal; in fact, Gal(␣1,3)Gal was expressed at the expense of Fuc(␣1,2)Gal (Figure 1b) . Cr release into the supernatant was determined as a measure of cell lysis. Three batches of sera were used: BTC and 58 (both from single donors), and Mix (pooled from six donors). Serum complement activity was confirmed by haemolytic assay (see Table 1 ) and by 51 Cr release from 3T3 cells (Figure 2e ). Assays were performed for ␣1,3GT-transduced and control cells using a fixed final concentration of 40% serum (Figure 2a-d) . TE671␣ cells were lysed efficiently by all three sera, but there was variable background lysis of nontransduced controls (presumably due to other cell reactivities because of the different origins of serum and target cells). All other Gal(␣1,3)Gal-positive cells were most sensitive to serum 58, without significant background, and least sensitive to BTC serum. This difference was most marked for HT1080␣ cells, which were not lysed by serum BTC. Overall, transduced EAhy926 cells were particularly resistant. In contrast, significant (30%) 51 Cr release with serum 58 from the second target of endothelial cell origin, ECV304, was seen for an unsorted population containing only approximately 30% ␣1,3GT-transduced cells (data not shown). Importantly, reactivity was not restricted to established cell lines but was also shown against cultured primary melanoma cells ( Figure  2c ). Since the last three cell targets were polyclonal their differential sensitivities cannot be attributed to clonal variation.
No significant 51 Cr-release was detected if serum was heat-inactivated (Figure 3) , demonstrating the necessity of functional complement for cell lysis. Furthermore, incubation of Gal(␣1,3)Gal-positive cells with serial dilutions of each of the three sera showed dose-dependent 51 Cr release (data not shown), indicating that serum is not saturating in this assay.
Cell lysis involves activation of the classical complement pathway by natural antibody
The specificity of lysis for expression of Gal(␣1,3)Gal epitopes was confirmed by addition of soluble sugars to serum before administration to the cells. The synthetic disaccharide Gal␣1-3Galactose (Gal␣1-3Gal) can bind specifically to anti-Gal antibodies in human serum (see Figure 4b ) and prevent anti-Gal-mediated complement activation;
13,17 as a control the disaccharide Gal␤1-4Gal was used. Pre-incubation of serum 58 with Gal␣1-3Gal disaccharide resulted in partial protection of Gal(␣1,3)Gal epitope expressing cells from lysis ( Figure 3 ). Only 30% of Mel␣ and less than 10% of 3T3 were lysed following pre-incubation, compared with 70% Mel␣ and 60% 3T3 without. In contrast, pre-incubation with the nonspecific disaccharide Gal␤1-4Gal gave little (3T3) or no (Mel␣) protection. The background reactivity against control melanoma cells was not inhibited by either disaccharide.
Serum 58 was depleted on HT1080␣ or HT1080 cells in
Figure 1 Cell surface expression of Gal(␣1,3)Gal. (a) Cell surface expression of Gal(␣1,3)Gal was detected by flow cytometry using FITC-BS-IB 4 . Human TE671␣ (panel 2), HT1080␣ (panel 3), Mel␣ (panel 4), and EAhy926␣ (panel 5) cells show high level expression of Gal(␣1,3)Gal, while control nontransduced cells (shaded) are negative. Murine 3T3 cells have endogenous ␣1,3GT activity (panel 1: the control shaded peak is without lectin). (b) EAhy926␣ cells have reduced levels of Fuc(␣1,2)Gal relative to nontransduced control cells (shaded). As indicated, cells were stained with FITC-BS-IB 4 for detection of Gal(␣1,3)Gal or FITC-UEA-I for detection of Fuc(␣1,2)Gal.
the presence of EDTA to prevent complement consumption, following which cells were removed and the depleted serum was supplemented with MgCl 2 and CaCl 2 . Despite some loss of complement activity, serum adsorbed against HT1080 cells retained significant activity in lysis of 3T3 cells, whilst adsorption against HT1080␣ cells completely abolished activity (data not shown). These experiments confirm the involvement of a serum component with specificity for the Gal(␣1,3)Gal epitope, consistent with the activation of complement by anti-Gal antibodies. Chelation of calcium ions, which are essential for initiation of the classical pathway of complement, by assay in the presence of EGTA/MgCl 2 , resulted in loss of more than 85% of the lytic activity of serum 58 towards HT1080␣ (data not shown). This excludes significant contribution from the alternative pathway, while the requirement for activation of the antibody-dependent classical pathway supports the involvement of anti-Gal antibody in lysis by human serum of human cells expressing Gal(␣1,3)Gal.
Analysis of serum components As mentioned above, there was substantial variation of sensitivity to lysis between the sera used. Variation was further shown when lysis with each of the sera comprising the pooled batch Mix was assayed (data not shown). Two possible sources of such variation are the levels of anti-Gal antibody and complement activity.
To determine the levels of Gal(␣1,3)Gal-specific antibodies in the different sera a solid phase ELISA using Gal␣1-3Gal␤1-4Glc␤1-BSA conjugate was performed. Antibody IgM and IgG levels were quantified separately ( Figure 4a ). The amount of IgM was similar for all three sera. However, the amount of IgG in serum BTC was 10-fold lower than the other sera, correlating with the weaker lytic activity of this serum. The specificity of the ELISA was verified using Gal␣1-3Gal or Gal␤1-4Gal disaccharides: IgG binding was blocked completely by Gal␣1-3Gal and partially by Gal␤1-4Gal, while IgM binding was significantly reduced by Gal␣1-3Gal and not at all by Gal␤1-4Gal (Figure 4b ). Incomplete inhibition of IgM binding suggests a greater specificity of this subtype towards the trisaccharide conjugate. 18 The levels of complement components C1q, C3 and C4 (which show the greatest variation between individuals) were determined for each of the sera used in this study (Table 1) , as well as the component sera of batch Mix (not shown). Despite small variations, which did not correlate with serum activity, the levels of these components and of overall complement haemolytic activity towards sheep red blood cells were all within the normal range.
Control of complement-mediated lysis by complement regulatory proteins
Human cells are protected against lysis by their expression of complement regulatory proteins. 19 In order to investigate the observed difference in susceptibility to complement-mediated lysis between different transduced cells flow cytometric analysis of their level of expression of CD46, CD55 and CD59 was performed ( Figure 5 ). CD59 was strongly expressed by all five, with only slight variation. The expression of CD55 was variable; TE671 showed weak expression, EAhy926 and HT1080 had strong expression; and that for ECV304 and melanoma was intermediate. CD46 also varied in the level of expression; TE671 and melanoma showed weak expression, while expression on the other three cell lines was strong. HT1080␣ and EAhy926␣ cells were the most resistant to lysis with sera BTC and Mix and expressed high levels of all three regulatory proteins. However, since all cells had high CD59 expression, ECV304 had high CD46 expression but were susceptible to lysis, and the most susceptible cells had weak CD55 expression, the closest correlation of resistance was to expression of CD55.
Since CD55 and CD59 are both anchored to the membrane via glycosyl phosphatidylinositol (GPI) their influence in protecting HT1080␣ cells was investigated using phosphatidylinositol-specific phospholipase C (PI-PLC) to remove them from the cell surface before testing for lysis by serum. Flow cytometry of HT1080␣ and HT1080 cells showed that CD55/CD59 expression was unaffected by ␣1,3GT transduction. Significantly reduced expression was detected after digestion with PI-PLC, with CD55 levels reduced to near background ( Figure  6a ). CD46, which is not anchored to the membrane via GPI, was unaffected by PI-PLC treatment. The level of Gal(␣1,3)Gal expression was also unaffected by this treatment (data not shown). Serum lysis was detected at a similarly high level (75-80%) for PI-PLC-treated HT1080␣ cells with all three sera, despite significant differences without such treatment (Figire 6b). The increase was most dramatic for serum BTC, for which no lysis was seen before PI-PLC treatment. No change was detected after treatment for nontransduced cells for sera BTC and Mix, but with serum 58 control cells showed 15% lysis after PI-PLC treatment. These results clearly show the protective role of the GPI-anchored complement regulatory proteins against complement-mediated lysis. However, serum-dependent factors are also important in determining the degree of lysis, since protection of HT1080␣ cells by these regulatory proteins was total against serum BTC but only partial for serum 58.
Our demonstration that Gal(␣1,3)Gal expression can activate complement to a degree sufficient to exceed the protection afforded by complement regulatory proteins implies that approaches to control hyperacute rejection by expression of such factors on donor cells are unlikely to be adequate. 20, 21 Indeed, extension of graft survival times of hearts from pigs transgenic for human CD55 and CD59 grafted into baboons was modest. 21 Selective lysis of ␣1,3GT expressing melanoma cells In order to study the selectivity of cell lysis towards ␣1,3GT expressing cells in the presence of non-modified cells we used a two-colour flow cytometric assay with propidium iodide staining indicative of lysis and BS-IB 4 staining to distinguish the cell populations. Mel␣ cells showed essentially complete lysis following incubation in serum 58, while non-modified melanoma cells were not lysed, corroborating the data obtained using the 51 Cr release assay. Detection of Gal(␣1,3)Gal with BS-IB 4 on lysed Mel␣ cells was still possible but at reduced fluorescence intensity, presumably reflecting the reduced availability of epitopes for binding by the lectin due to their occupation by antibodies. A bulk population of melanoma cells infected with the retroviral vector encoding ␣1,3GT containing approximately 60% high expressing cells (from which the Mel␣ sorted cells were derived) was similarly tested. The two populations were clearly identifiable both before and after serum treatment, with lysis selective for the Gal(␣1,3)Gal-positive cells ( Figure  7 ).
Discussion
The present study describes a new strategy for gene therapy of cancer as an alternative to enzyme prodrug activation or immunotherapy approaches. This strategy is based on the fact that naturally occurring antibodies in human serum react with cells of discordant species due to recognition of an abundant specific surface antigen, 
Cr specific release was determined. Data shown are means and standard errors from five replicates. Target cells were nontransduced controls (stippled bars) and ␣1,3GT transduced (filled bars) TE671 (a), HT1080 (b), melanoma (c) and EAhy926 (d). Lysis of 3T3 cells (e) is also shown.
Gal(␣1,3)Gal. The ensuing complement activation results in hyperacute rejection of such xenografts. 9 The same mechanism leads to rejection even between the phylogenetically close New and Old World primates. 22 We propose to mimic this response and harness the potency of the complement system as a means of eliminating human cells. Sensitisation of a panel of human cells, including cultured primary tumour cells, in the presence of human serum was observed following expression of ␣1,3GT to generate the terminal Gal(␣1,3)Gal sugar structures. Importantly, it was possible to achieve lysis despite expression of complement regulatory proteins. Moreover, in a mixed population of melanoma cells lysis was restricted to those expressing ␣1,3GT, suggesting the potential for selectivity in vivo by targeted expression.
Expression of ␣1,3GT led to sensitisation for five human cell targets, including two endothelial cell lines and a primary melanoma cell culture. However, the extent of lysis was variable. First, variability depended on the choice of human serum. To investigate this variation several serum components were tested. Complement components C1q, C3 and C4, as well as complement activity showed little variation and all sera gave values in the normal range. The most significant finding was a 10-fold lower anti-Gal IgG titre for serum BTC compared with the other sera used; IgM levels were similar. Reduced specific IgG is likely related to the AB blood group of this donor, due to the similarity of the B antigen to Gal(␣1,3)Gal. 23 Second, for a given serum the extent of lysis depended on the target cell, despite equivalent high level expression of Gal(␣1,3)Gal. Serum BTC showed the most marked difference, with little or no lysis of HT1080␣ and EAhy926␣ but total lysis of TE671␣. This target cell variation correlated most closely with expression of CD55. Moreover, lysis was shown to be controlled by the GPIanchored complement regulatory proteins (including CD55 and CD59), since treatment of the relatively resistant HT1080␣ cells with PI-PLC resulted in efficient lysis by all three sera. Apparently the low anti-Gal IgG titre of serum BTC is of no consequence in the absence of CD55/59. Others have similarly reported that CD55 expression correlates inversely with the sensitivity of gliomas and ovarian tumours to complement following binding of sensitising antibodies. 24, 25 Lysis of HT1080␣ cells with serum BTC was observed following binding to CD59 but not CD55 using the monoclonal antibodies BRIC216 and BRIC229, respectively (data not shown). This indicates the functional importance of CD59 but does not exclude CD55 since the latter antibody does not neutralise function. 24 From the foregoing discussion it seems likely that the extent of lysis observed in vitro is due to the balance of complement activation and intrinsic resistance for a given combination of serum and target cells. Importantly, lysis can be achieved with serum alone, exploiting pre-existing natural antibody. Gal(␣1,3)Gal epitope expression on transduced human cells is abundant, as on 3T3 cells, and is unlikely to be a limiting factor. Rather, the magnitude of complement activation appears to be limited by a serum component in vitro. Continued exposure of cells to fresh serum may saturate the protective mechanisms of even the most resistant cells, in which case protection due to regulatory proteins will have little importance for in vivo complement activation. Under such non-limiting conditions anti-Gal binding to modified CD55 and CD59, themselves glycoproteins, may further limit their ability to regulate complement.
Figure 6 PI-PLC digestion of target cells. HT1080␣ and nontransduced control cells were untreated or treated with PI-PLC to determine the influence of GPI-linked complement regulatory proteins. (a) Surface expression of CD46, CD55 and CD59 for HT1080␣ cells was determined by flow cytometry to verify removal of GPI
Although our in vitro studies have concentrated on complement activation leading to lysis, other immunological sequelae can be envisaged and may be at least as important in vivo. For instance, C5a is chemotactic, leading to recruitment of macrophages, and surfacedeposited C3b targets cells to C3 receptor-bearing phagocytes. Additionally, opsonisation by antibody binding to Gal(␣1,3)Gal epitopes on tumour cell membrane fractions released after lysis is likely to lead to F c receptor uptake and augmentation of autologous tumour associated antigen presentation by antigen presenting cells. Using this rationale a strategy to engineer tumour cell membranes to express Gal(␣1,3)Gal epitopes by desialylation and enzyme modification has been proposed to enhance the efficacy of tumour vaccines. 26, 27 Platelet and fibrin thrombus formation may also follow complement fixation by modified endothelial cells, for which activation rather than lysis may be sufficient. 1 For in vivo application, as with all proposed gene therapy approaches, it will be important to restrict ␣1,3GT expression to specific cells to induce only their lysis by complement. This will necessitate targeted delivery and/or transcriptional activity of the vector. In addition, it is also important that there is no undesired side-effect on unmodified cells. Since the effect is mediated by serum without the involvement of other drugs this is likely to be the case in vivo. This represents a major advantage over prodrug activation approaches, which often suffer from a narrow therapeutic index due to prodrug-associated toxicity. A further advantage for clinical application of this approach is the fact that all humans have natural antibodies against the Gal(␣1,3)Gal epitope, although the proportion of individuals with low affinity anti-Gal antibody increases in the elderly. 28 Immunisation with the sugar epitope is a possible way to increase titres of anti-Gal antibodies if this poses a limitation.
In conclusion, we have shown that cell surface expression of the Gal(␣1,3)Gal epitope at high levels leads to complement activation and cell lysis of human cells by human serum. Therefore, expression of (␣1,3)galactosyl transferase represents a promising new therapeutic approach for gene therapy of cancer by mimicry of hyperacute rejection.
Materials and methods
Cells and retroviral vector Murine NIH3T3 fibroblasts, human rhabdomyosarcoma cell line TE671, human fibrosarcoma cell line HT1080, human endothelial cell lines derived from umbilical cord, EAhy926 and ECV304, and a primary melanoma cell culture derived from a patient with malignant melanoma 29 were maintained in DMEM supplemented with 10% FCS.
A 2.0 kb BamHI fragment of plasmid pS␣13GT containing the cDNA for porcine ␣1,3GT
30 was cloned into the BamHI site of the retroviral vector MFG. 31 A high titre (5 × 10 6 /ml) vector producing clone of the amphotropic retrovirus packaging cell line FLY A13 32 was selected following cotransfection with pSV 2 neo. Producer cells were maintained as above. Supernatant was harvested after overnight incubation and filtered (0.45 m) before use. Target cells were infected in the presence of 8 g/ml polybrene. Forty-eight hours later cells were assayed by flow cytometry to determine the level of cell surface expression of Gal(␣1,3)Gal.
Flow cytometry Cells were detached in 0.02% EDTA/PBS, washed and stained with 10 g/ml FITC-conjugated Bandeiraea simplicifolia isolectin B 4 (BS-IB 4 ) (Sigma, Poole, UK) to assess Gal(␣1,3)Gal expression. Fuc(␣1,2)Gal expression was similarly detected using Ulex europaeus lectin UEA-I. To determine expression of complement regulatory proteins cells were stained with mouse anti-human CD55 (IgG) or CD46 (IgG) (Cymbus Bioscience, Southampton, UK) diluted 1:20, or rat anti-human CD59 (IgG2b, clone YTH53.1, a gift from P Lachmann 33 ) diluted 1:5000. After washing, appropriate FITC-conjugated secondary antibodies were used for detection. Control cells were stained with the secondary antibody only.
For flow sorting, 10 7 cells were stained with 10 g/ml BS-IB 4 and Gal(␣1,3)Gal high-expressing cells were selected using a Becton Dickinson FACStar (Oxford, UK). Cells were washed several times with medium and seeded on six-well plates. Cells were grown for several days and tested again for expression of Gal(␣1,3)Gal before further use.
Human sera
The following human sera were used in this study. Serum batch BTC (from the North London Blood Transfusion Centre) was from a single donor with blood group AB Rh A total haemolytic complement kit (The Binding Site, Birmingham, UK) was used for measuring complement activity. The following assays were performed at the Rheumatology Unit, Royal Postgraduate Medical School, Hammersmith Hospital. Serum concentrations of C1q were determined using a sandwich ELISA technique. C3 and C4 were assayed by radial immunodiffusion. Serum haemolytic complement levels were assayed using a plate assay with sheep red blood cells sensitised with rabbit serum.
51
Cr release assay for cell lysis Cells were washed with PBS and detached with 0.02% EDTA/PBS. After washing, 1 × 10 6 cells were resuspended in 50 l (50 Ci) sodium chromate ( 51 Cr) (Amersham International, Buckinghamshire, UK) and incubated for 1 h at 37°C. Cells were pelleted, resuspended in 10 ml medium and incubated for a further 30 min at 37°C before washing twice in OptiMEM (Life Technologies, Paisley, UK) and resuspending in Opti-MEM to a concentration of 5 × 10 5 cells/ml. 50 l cells (2.5 × 10 4 ) were added to 100 l serum, 1% NP-40 or Opti-MEM in a 96-well V-bottom microtitre plate; five replicates were performed. After incubation for 2-3 h at 37°C cells were pelleted at 210 g for 3 min and 80 l supernatant was removed and measured with a gamma counter (Gamma 5500B; Beckman Instruments, Buckinghamshire, UK). Specific release (%) of 51 Cr was determined by the following formula:
(release with serum − release with OptiMEM) × 100 (release with 1% NP-40 − release with OptiMEM)
The standard error of the specific release was calculated from the means and variances of the different treatments. 34 To determine the requirement for complement serum was heat-inactivated for 30 min at 56°C before use. To determine the contribution of the classical pathway serum was pre-incubated with 10 mm EGTA and 2.5 mm MgCl 2 for 1 h. For sugar blocking experiments serum was incubated with 5 mg/ml Gal␣1-3Gal or Gal␤1-4Gal disaccharides (Dextra Laboratories, Reading, UK) for 1 h at 4°C before assay.
PI-PLC treatment
Cells (1 × 10 6 ) were incubated with 0.1 U phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis (Oxford GlycoSystems, Oxford, UK) in 1 ml PBS for 1 h at 37°C. After incubation, cells were washed and used for flow cytometry or 51 Cr-release assay.
Detection of anti-Gal antibodies by solid-phase ELISA Ninety-six-well plates (Nunc Polysorp; Life Technologies) were coated overnight at 4°C with 50 l per well of 10 g/ml Gal␣1-3Gal␤1-4GlcNAc␤1-BSA conjugate (Dextra Laboratories), or BSA as control, in 0.1 m bicarbonate buffer (pH 9.6). 0.05% Tween/PBS was used for washing. Nonspecific binding was blocked with 200 l 2% polyvinylpyrolidone for 4 h at room temperature. Test serum was pre-incubated with 2% BSA for 1 h to block potential human anti-BSA. 50 l serial dilutions of serum were then incubated for 1 h at room temperature, in duplicate. Binding of IgG or IgM was quantified by incubating with peroxidase-conjugated rabbit antihuman IgG and IgM (DAKO, Buckinghamshire, UK) at a dilution of 1:1000, for 1 h at room temperature, followed by the substrate reaction with 1,2 phenylenediamine. Plates were read at 490 nm and specific binding was calculated by subtracting the average optical density in BSA-coated wells from that in antigen-coated wells. 18 In order to verify the specificity of this assay, serum was pre-incubated with 5 mg/ml Gal␣1-3Gal or Gal␤1-4Gal disaccharides, as above.
Assay for cell lysis by propidium iodide uptake and flow cytometry Cells were washed with PBS and detached with 0.02% EDTA/PBS. After washing, 5 × 10 5 cells were incubated in 500 l 70% serum or OptiMEM for 2 h at 37°C. The cells were washed and subsequently stained with 10 g/ml FITC-conjugated BS-IB 4 , followed by 0.5 g/ml propidium iodide, for analysis by flow cytometry.
